Black Friday Get Elite for just $149.00 Claim Now

2 Cancer-Drug Developers Seeing Unusual Options Volume

By Laura McCandless | November 16, 2026, 1:01 PM

Two cancer drug developers are seeing unusual options activity today, with Summit Therapeutics Inc (NASDAQ:SMMT) and CG Oncology Inc (NASDAQ:CGON) moving in opposite directions following major clinical and regulatory developments. Despite the contrasting price action, options traders are leaning bearish on both stocks.

SMMT stock is plunging 15% to trade at $12.02, earlier hitting a two-year low after the Food and Drug Administration (FDA) declined to approve its lung cancer drug ivonescimab, requesting additional evidence that the treatment improves overall survival. Citi also lowered its price target to $42 from $43. Options volume is running at 6.3 times the usual intraday pace, with 60,032 contracts exchanged and negative net option delta volume of roughly 86,000 shares.

CGON is soaring 12.5% to trade at $83.70, trading at record highs after its Phase 3 PIVOT-006 trial met its primary endpoint. The company's bladder cancer treatment reduced the risk of recurrence by 68% compared to the control group. Despite the rally, options sentiment is bearish, with negative net option delta volume of roughly 207,000 shares. So far, 14, 065 contracts have crossed the tape, or seven times the average intraday volume.

Latest News

Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16
Nov-16